Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29910754 | 0.84 | GPR84 (0.37) | CA2 | |
| SCHEMBL9117823 | 0.84 | GPR84 (0.37) | CA2 | |
| SCHEMBL7598022 | 0.83 | THRB (0.33) | — | |
| SCHEMBL6705355 | 0.82 | TSHR (0.42) | — | |
| SCHEMBL1445658 | 0.79 | PTGS1 (0.30) | — | |
| SCHEMBL29087907 | 0.79 | PTGS1 (0.30) | — | |
| SCHEMBL1742940 | 0.78 | CA2 (0.30) | CA2 | |
| SCHEMBL1741194 | 0.78 | LMNA (0.32) | CA2 | |
| SCHEMBL4034122 | 0.78 | — | — | |
| SCHEMBL1741192 | 0.78 | LMNA (0.32) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119630672-A | Camptothecin derivative and conjugate thereof, and preparation method and medical application thereof | 一线医药（杭州）有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20080207936-A1 | Chemical intermediate for drugs; reduction of the corresponding 3-hydroxybutyrate ; then oxidation using nitroxyl compound and co-oxidizer | KANEKA CORPORATION (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1862465-A1 | METHOD OF PRODUCING 3-HYDROXYBUTYRALDEHYDE DERIVATIVE | Kaneka Corporation (JP) | 2007-12-05 | — | — | EP | disclosed |
| WO-1997046525-A1 | 5-ALKOXY-TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS 5-HT1D RECEPTOR AGONISTS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207936-A1 | Chemical intermediate for drugs; reduction of the corresponding 3-hydroxybutyrate ; then oxidation using nitroxyl compound and co-oxidizer | CYP11B2, CYP11B1, ADH5 | CA2 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.